Khalid Jadoon

• Doctor of Philosophy
• Consultant at National Health Service

Background: Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate if CBD reduces BP in humans. Methods: Nine healthy male...

Background and purpose: We have shown that in vitro treatment with cannabidiol (CBD, 2 h) enhances endothelial function in arteries from Zucker diabetic fatty (ZDF) rats, partly due to a cyclooxygenase (COX)-mediated mechanism. The aim of the present study was to determine whether treatment with CBD in vivo would also enhance endothelial function....

Metabolic syndrome, first described as Syndrome X, includes a cluster of metabolic abnormalities including visceral obesity, insulin resistance, dyslipidaemia and hypertension. The pathophysiology of metabolic syndrome is complex, however, visceral adiposity and insulin resistance are thought to play a central role and both are implicated in the de...

Objective: Cannabidiol (CBD) and Δ(9)-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes. Research design and methods: In this randomized, double-blind, placebo-controlled study,...

The induction of glycosuria using phlorizin, a nonselective inhibitor of renal and intestinal transport was well recognized to lower glucose levels and induce calorie loss in animal models of diabetes. Phlorizin and other similar molecules however were not suitable for clinical use due to adverse effects of non selective inhibition of extra-renal g...